Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Apitolisib (formerly also known as GDC0980, RG7422, GNE390) is a novel, potent, selective and orally bioavailable class I PI3K inhibitor with potential anticancer activity. In cell-free assays, it inhibits PI3K with an IC50 of 5 nM, 27 nM, 7 nM, and 14 nM, respectively. Additionally, it is a highly selective inhibitor of other PIKK family kinases and a potent mTOR inhibitor with a Ki of 17 nM in a cell-free assay. Apitolisib is a dual PI3 kinase/mTOR inhibitor with potential anticancer activity that also targets the PI3K/mTOR signaling pathway's phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase. Apoptosis in tumor cells and growth inhibition in cancer cells overexpressing PI3K/mTOR may result from apatolisib's inhibition of both PI3K kinase and mTOR kinase.
Targets |
PI3Kα (IC50 = 5 nM); PI3Kδ (IC50 = 7 nM); PI3Kγ (IC50 = 14 nM); PI3Kβ (IC50 = 27 nM); mTOR (Ki = 17 nM); TORC1; TORC2
|
---|---|
ln Vitro |
Apitolisib (GDC-0980) is remarkably selective for a number of other members of the related PIKK family kinases, including C2alpha, C2beta, VPS34, PI4Kalpha, PI4Kbeta, and DNA-PK, with IC50 values of 1300 nM, 794 nM, 2000 nM, and 623 nM, respectively[1]. According to a recent study, apitolisib (GDC-0980) inhibits cell-cycle progression and induces apoptosis, with the greatest effectiveness against prostate, breast, and NSCLC cell lines (IC50 200 nM 29%, 500 nM 88%), and the least effectiveness against pancreatic and melanoma cell lines (IC50 200 nM 0%, 500 nM 33%)[2].
|
ln Vivo |
Apitolisib (GDC-0980) (1 mg/kg, p.o.) is undergoing phase I clinical trials for cancer and has shown significant efficacy in mouse xenografts. Apitolisib (GDC-0980) exhibits dose-proportional exposure from 5 mg/kg dosed in PEG to 50 mg/kg dosed in suspension in MCT, a finding that has been partially attributed to the drug's good solubility[1]. Clearance and PPB are also low. In 15 of the 20 xenograft models, apatolisib (GDC-0980) (5 mg/kg, p.o.) causes more than 50% TGI. The length of time that pAkt/tAkt has been knocked down is correlated with the variation in tumor response to Apitolisib (GDC-0980) therapy[2].
|
Enzyme Assay |
Enzymatic activity of the Class I PI3K isoforms is measured using a fluorescence polarization assay that monitors formation of the product 3,4,5-inositoltriphosphate molecule as it competes with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidyl inositide-3-phosphate product results in a decrease in fluorescence polarization signal as the labeled fluorophore is displaced from the GRP-1 protein binding site. Class I PI3K isoforms are expressed and purified as heterodimeric recombinant proteins. PI3K isoforms are assayed under initial rate conditions in the presence of 10 mM Tris (pH 7.5), 25 μM ATP, 9.75 μM PIP2, 5% glycerol, 4 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 2% (v/v) DMSO at the following concentrations for each isoform: PI3Kα,β at 60 ng/mL; PI3Kγ at 8 ng/mL; PI3Kδ at 45 ng/mL. After assay for 30 minutes at 25°C, reactions are terminated with a final concentration of 9 mM EDTA, 4.5 nM TAMRA-PIP3, and 4.2 μg/mL GRP-1 detector protein before reading fluorescence polarization on an Envision plate reader. IC50s are calculated from the fit of the dose−response curves to a 4-parameter equation.Human recombinant mTOR(1360−2549) is expressed and purified from insect cells and assayed using a Lanthascreen fluorescence resonance energy transfer format in which phosphorylation of recombinant green fluorescent protein (GFP)-4-EBP1 is detected using a terbium-labeled antibody to phospho-threonine 37/46 of 4-EBP1. Reactions are initiated with ATP and conducted in the presence of 50 mM Hepes (pH 7.5), 0.25 nM mTOR, 400 nM GFP-4E-BP1, 8 μM ATP, 0.01% (v/v) Tween 20, 10 mM MnCl2, 1 mM EGTA, 1 mM dithiothreitol, and 1% (v/v) DMSO. Assays are conducted under initial rate conditions at room temperature for 30 minutes before terminating the reaction and detecting product in the presence of 2 nM Tb-anti-p4E-BP1 antibody and 10 mM EDTA. Dose−response curves are fit to an equation for competitive tight-binding inhibition and apparent Ki' s are calculated using the determined Km for ATP of 6.1 μM.
|
Cell Assay |
Antiproliferative cellular assays are conducted using PC3 and MCF7.1 human tumor cell lines. MCF7.1 is an in vivo selected line and originally derived from the parental human MCF7 breast cancer cell line. Cell lines are cultured in RPMI supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin, 10 mM HEPES, and 2 mM glutamine at 3°C under 5% CO2. MCF7.1 cells or PC3 cells are seeded in 384-well plates in media at 1000 cells/well or 3000 cells/well, respectively, and incubated overnight prior to the addition of GDC-0980 to a final DMSO concentration of 0.5% v/v. MCF7.1 cells and PC3 cells are incubated for 3 days and 4 days, respectively, prior to the addition of CellTiter-Glo reagen and reading of luminescence using an Analyst plate reader. For antiproliferative assays, a cytostatic agent such as aphidicolin and a cytotoxic agent such as staurosporine are included as controls. Dose−response curves are fit to a 4-parameter equation and relative IC50s are calculated using Assay Explorer software.
|
Animal Protocol |
In Hank's Balanced Salt Solution, human prostate cancer PC3 cells are reconstituted, and 3 106 cells are implanted subcutaneously into the right hind flank of athymic nu/nu (nude) mice. Prior to starting treatment, tumors are watched until their mean tumor volume reaches 150–200 mm3. Athymic nu/nu (nude) mice with the right hind flank subcutaneously implanted with 5106 MCF7.1 cells that have been resuspended in a 1:1 mixture of Hank's Buffered Salt Solution and Matrigel Basement Membrane Matrix. Each naked mouse has a 0.36 mg/pellet of 17-estradiol (60-day release, no. SE-121) implanted beneath its dorsal shoulder blade before the cell inoculation. Tumors are watched after cell implantation until their mean tumor volume reaches 250–350 mm3 before dosing begins. 0.5% methylcellulose and 0.2% Tween-80 (MCT) are used to dissolve compound 2. Charles River Laboratories provides female nude (nu/nu) mice that are 20-30 g in weight, 6-8 weeks old, and in this condition. Depending on the xenograft model, tumor-bearing mice receive daily oral doses of 100 L of the test agent or vehicle (MCT) for 14–21 days.
|
References |
|
Molecular Formula |
C23H30N8O3S
|
---|---|
Molecular Weight |
498.6011
|
Exact Mass |
498.22
|
Elemental Analysis |
C, 55.40; H, 6.06; N, 22.47; O, 9.63; S, 6.43
|
CAS # |
1032754-93-0
|
Related CAS # |
1032754-93-0
|
Appearance |
white solid powder
|
SMILES |
C[C@H](O)C(N1CCN(CC2=C(C)C3=NC(C4=CN=C(N)N=C4)=NC(N5CCOCC5)=C3S2)CC1)=O
|
InChi Key |
YOVVNQKCSKSHKT-HNNXBMFYSA-N
|
InChi Code |
InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1
|
Chemical Name |
(S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one.
|
Synonyms |
GNE-390; GNE390; Apitolisib; GDC0980; GDC-0980; RG-7422; RG 7422; GNE 390; GDC 0980; RG7422
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~20 mg/mL (40.1 mM)
Water: <1 mg/mL Ethanol: <1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.43 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.43 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.43 mg/mL (2.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 0.5% methylcellulose+0.2%Tween 80: 30 mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0056 mL | 10.0281 mL | 20.0562 mL | |
5 mM | 0.4011 mL | 2.0056 mL | 4.0112 mL | |
10 mM | 0.2006 mL | 1.0028 mL | 2.0056 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Status | Interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01485861 | Completed | Drug: Abiraterone Drug: Apitolisib |
Prostate Cancer | Genentech, Inc. | January 11, 2012 | Phase 1 Phase 2 |
td> |
Mol Cancer Ther, 2011, 10(12), 2426-2436. |